These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37854158)

  • 21. Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer.
    Fujiwara M; Fujiwara R; Urasaki T; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
    Anticancer Res; 2022 Apr; 42(4):2045-2051. PubMed ID: 35347027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?
    Sert F; Cosgun G; Yalman D; Ozkok S
    Cancer Radiother; 2021 Jun; 25(4):316-322. PubMed ID: 33422415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Lim JU; Kang HS; Yeo CD; Kim JS; Park CK; Kim JW; Kim SJ; Lee SH
    J Thorac Dis; 2021 May; 13(5):2824-2832. PubMed ID: 34164174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Ishihara M; Ochiai R; Haruyama T; Sakamoto T; Tanzawa S; Honda T; Ota S; Ichikawa Y; Ishida T; Watanabe K; Seki N
    Transl Lung Cancer Res; 2021 Jan; 10(1):221-232. PubMed ID: 33569306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.
    Banna GL; Cortellini A; Cortinovis DL; Tiseo M; Aerts JGJV; Barbieri F; Giusti R; Bria E; Grossi F; Pizzutilo P; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Marco R; Cantini L; Nigro O; D'Argento E; Buti S; Minuti G; Landi L; Guaitoli G; Lo Russo G; De Toma A; Donisi C; Friedlaender A; De Giglio A; Metro G; Porzio G; Ficorella C; Addeo A
    ESMO Open; 2021 Apr; 6(2):100078. PubMed ID: 33735802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.
    Kotha NV; Cherry DR; Bryant AK; Nalawade V; Stewart TF; Rose BS
    Clin Transl Radiat Oncol; 2021 May; 28():133-140. PubMed ID: 33997320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
    Banna GL; Signorelli D; Metro G; Galetta D; De Toma A; Cantale O; Banini M; Friedlaender A; Pizzutillo P; Garassino MC; Addeo A
    Transl Lung Cancer Res; 2020 Aug; 9(4):1533-1542. PubMed ID: 32953525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Fujimoto A; Toyokawa G; Koutake Y; Kimura S; Kawamata Y; Fukuishi K; Yamazaki K; Takeo S
    Thorac Cancer; 2021 Aug; 12(15):2198-2204. PubMed ID: 34173724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
    Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
    Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score.
    Galvano A; Peri M; Guarini AA; Castiglia M; Grassadonia A; De Tursi M; Irtelli L; Rizzo S; Bertani A; Gristina V; Barraco N; Russo A; Natoli C; Bazan V
    Ther Adv Med Oncol; 2020; 12():1758835920942378. PubMed ID: 32849916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined C-reactive protein and Neutrophil to Lymphocyte ratio use predict survival innon-small-cell lung cancer.
    Bacha S; Sghaier A; Habibech S; Cheikhrouhou S; Racil H; Chaouch N; Zaouri B; Chabbou A
    Tunis Med; 2017 Dec; 95(12):229-235. PubMed ID: 29878284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 37. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
    Tjokrowidjaja A; Lord SJ; John T; Lewis CR; Kok PS; Marschner IC; Lee CK
    Cancer; 2022 Apr; 128(8):1574-1583. PubMed ID: 35090047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
    Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
    J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
    Navani V; Meyers DE; Ruan Y; Boyne DJ; O'Sullivan DE; Dolter S; Grosjean HA; Stukalin I; Heng DYC; Morris DG; Brenner DR; Sangha R; Cheung WY; Pabani A
    Clin Lung Cancer; 2023 May; 24(3):e152-e159. PubMed ID: 36774234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy.
    Riemann D; Turzer S; Ganchev G; Schütte W; Seliger B; Möller M
    Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.